secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001619856-24-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus
-------------------------------------------------------------------------

- Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.
- Cash, cash equivalents, and marketable securities $345.9M as of Mar 31, 2024, funding operations into Q1 2026.
- FDA IND clearance for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 trial expected to start by YE 2024.
- Plans to present initial CB-010 dose expansion data at ASCO June 3, 2024; initial CB-011 data by YE 2024.
- Licensing and collaboration revenue $2.4M, down from $3.5M due to terminated AbbVie agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/0001619856-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/crbu-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer